Cefdinir for Recent-Onset Pediatric Neuropsychiatric Disorders: A Pilot Randomized Trial
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Previous studies suggest that the unexplained sudden and severe onset of obsessive-compulsive disorder (OCD) and/or tics may be infection or immune precipitated. Beta lactam antibiotics may be neuroprotective beyond their antimicrobial efficacy. We examine the preliminary safety and efficacy of cefdinir in reducing obsessive-compulsive and/or tic severity in children with new-onset symptoms. METHOD: Twenty subjects were randomized to receive placebo or cefdinir for 30 days for the treatment of recent-onset OCD and/or tics. The placebo group received a comparable inactive treatment matched for taste, color, and consistency. The Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) and Yale Global Tic Severity Scale (YGTSS) were the primary outcome measures utilized. RESULTS: Subjects receiving cefdinir saw notable improvements in tic symptoms, with 44.4% showing at least a 25% reduction in YGTSS (mean decrease=9.5) scores compared with 9.1% of the placebo group (mean decrease=0.13). Despite improvements, significant group differences were not observed for YGTSS (F [1, 13]=4.03, p=0.066) although there were moderate differences between group treatment effects (d=0.72). For OCD symptoms, subjects receiving cefdinir saw improvements in OCD symptoms, with 33.3% showing at least a 25% reduction in CY-BOCS scores (mean decrease=7.8) compared with 27.3% of the placebo group (mean decrease=4.7), but there were also no significant differences for CY-BOCS (F [1, 13]=0.385, p=0.546; d=0.24). CONCLUSIONS: Subjects assigned to cefdinir exhibited notable, albeit nonstatistically significant, improvements in tic symptoms, compared with the placebo group. There were also some improvements in OCD symptoms, although these were not significant. Overall, cefdinir was well tolerated. Given these preliminary results, a fully powered study is warranted to explore the efficacy of cefdinir as a therapeutic tool for new-onset pediatric neuropsychiatric symptoms, particularly those that appear to be precipitated by infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The yale global tic severity scale: initial testing of a clinician-rated scale of tic severity
LECKMAN, J. F., RIDDLE, M. A., HARDIN, M. T., ORT, S. I., SWARTZ, K. L., STEVENSON, J., & COHEN, D. J. (1989) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-198907000-00015 · Cited by 2,146
Children's Yale-Brown Obsessive Compulsive Scale: Reliability and Validity
SCAHILL, L., RIDDLE, M. A., McSWIGGIN-HARDIN, M., ORT, S. I., KING, R. A., GOODMAN, W. K., CICCHETTI, D., & LECKMAN, J. F. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199706000-00023 · Cited by 2,045 · cited 2×
“All assessments were conducted or reviewed by the first author or, for the Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS) (Scahill et al. 1997), the Yale Global Tic Severity Scale (YGTSS) (Leckman et al. 1989), and the Clinical Global Impressions Scale (CGI) (Busner and Targum 2007), by…”
Swedo, S. E., Leonard, H. L., Garvey, M., Mittleman, B., Allen, A. J., Perlmutter, S., Dow, S., Zamkoff, J., Dubbert, B. K., & Lougee, L. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.2.264 · Cited by 1,534
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518 · cited 1×
“Recent studies have highlighted the neuroprotective properties of b -lactam antibiotics beyond their antimicrobial efficacy, when found to promote the expression of glutamate transporter GLT1, a neurotransmitter system also implicated in OCD and tic disorder (Rothstein et al. 2005).”
Immune involvement in schizophrenia and autism: Etiology, pathology and animal models
Patterson, P. H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.12.016 · Cited by 766 · cited 1×
“In schizophrenia, for example, perinatal insults resulting in immune activation have been linked to the occurrence of the disorder, particularly the neuropathological, behavioral, and immune abnormalities observed in these patients (Patterson 2009; Winter et al. 2009; Brown 2012).”
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426 · cited 2×
“…unknown, although genetic predisposition and neurotransmitter dysfunction have been among the most prominent theories, with evidence of a familial association as well as abnormalities in serotonin, dopamine, and glutamate systems (Adams et al. 2005; Lazar et al. 2008; Pittenger et al. 2011).”
High prevalence of obsessive–compulsive symptoms in patients with Sydenham's chorea
(1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.2.246 · Cited by 421
Winter, C., Djodari-Irani, A., Sohr, R., Morgenstern, R., Feldon, J., Juckel, G., & Meyer, U. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009206 · Cited by 242 · cited 1×
“In schizophrenia, for example, perinatal insults resulting in immune activation have been linked to the occurrence of the disorder, particularly the neuropathological, behavioral, and immune abnormalities observed in these patients (Patterson 2009; Winter et al. 2009; Brown 2012).”
Snider, L. A., Lougee, L., Slattery, M., Grant, P., & Swedo, S. E. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.035 · Cited by 237
Obsessive–compulsive disorder comorbidity: Clinical assessment and therapeutic implications
Pallanti, S., Grassi, G., Sarrecchia, E. D., Cantisani, A., & Pellegrini, M. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00070 · Cited by 158 · cited 2×
“…comorbid tics, for example, are likely to be less responsive to serotonin reuptake inhibitor (SSRI) treatment than their counterparts without tics (March et al. 2007; Pallanti et al. 2011), and those with PANDAS may be more prone to behavioral activation with antidepressants (Murphy et al. 2006).”
Cited by
Thienemann, M., Murphy, T., Leckman, J., Shaw, R., Williams, K., Kapphahn, C., Frankovich, J., Geller, D., Bernstein, G., Chang, K., et al. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0145 · Cited by 149
“PANS patients with tics have been reported to be more severely affected at home and at school, with poorer school performance, handwriting, visual-spatial memory, and self-esteem (Murphy et al. 2015).”
BackgroundInfluentialSelf-citationWilliams, K. A., Swedo, S. E., Farmer, C. A., Grantz, H., Grant, P. J., D’Souza, P., Hommer, R., Katsovich, L., King, R. A., & Leckman, J. F. (2016) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2016.06.017 · Cited by 124
Overview of treatment of pediatric acute-onset neuropsychiatric syndrome
Swedo, S. E., Frankovich, J., & Murphy, T. K. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0042 · Cited by 104
Self-citationMurphy, T. K., Brennan, E. M., Johnco, C., Parker-Athill, E. C., Miladinovic, B., Storch, E. A., & Lewin, A. B. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0190 · Cited by 58
“More recently, Murphy et al. (2015a) conducted a placebo-controlled trial examining the preliminary safety and efficacy of a 30-day treatment dose of cefdinir in reducing symptom severity in youth aged 4–13 with a recent onset of OCD and/or tics ( N = 28), but not all meeting full PANS/PANDAS…”
InfluentialSelf-citationThe PANDAS Controversy: why (and How) Is It Still Unsettled?
Murphy, T. K., Gerardi, D. M., & Parker-Athill, E. C. (2014) · Current Developmental Disorders Reports · doi:10.1007/s40474-014-0025-3 · Cited by 14
Self-citation
Metadata
- Authors
- Murphy, T. K., Parker-Athill, E. C., Lewin, A. B., Storch, E. A., & Mutch, P. J.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2015-02
- Volume
- 25
- Issue
- 1
- Pages
- 57-64
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2047290261
- Cited by
- 51
- References
- 12
- FWCI
- 7.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cefdinir for Recent-Onset Pediatric Neuropsychiatric Disorders: A Pilot Randomized Trial. https://app.cochat.ai/papers/10.1089/cap.2014.0010
- The paper
- Murphy, T. K., Parker-Athill, E. C., Lewin, A. B., Storch, E. A., & Mutch, P. J. (2015). Cefdinir for Recent-Onset Pediatric Neuropsychiatric Disorders: A Pilot Randomized Trial. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2014.0010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.